OR WAIT null SECS
May 16, 2024
Breyanzi is made from the patient’s own T cells, which are genetically reengineered into CAR-T cells and then delivered through infusion as a one-time treatment.
The new drug delivery site will serve to increase Cresset's reach in the region, answering growing demands from its Asia-Pacific consumers.
The company presented results from its programs for Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy.
May 14, 2024
One of the first planned areas of focus is the field of preterm birth-associated early onset respiratory disease.
May 10, 2024
Studies conducted by a team at Oxford Biomedica demonstrated that HIC can be used to effectively separate non-deamidated capsids from deamidated capsids.
Regeneron’s work in CAR-T cell therapy development includes engineering receptor architecture to improve CAR-T cell sensitivity and improve immune response.
Sven Moller-Tank, PhD, director of Viral Delivery Technologies, Regeneron Genetic Medicines, Regeneron spoke about the use of bispecific antibodies to retarget AAV specificity.
May 08, 2024
Broken String Biosciences and the Francis Crick Institute will collaborate on research into how genome stability impacts ALS.
The company’s presentation at ASGCT includes preliminary data results for a child who received the gene therapy.
The company is presenting preclinical data at the American Society of Gene & Cell Therapy annual meeting that supports the potential of the company’s CAP-002 gene therapy for correcting neurological phenotypes associated with genetic epilepsy due to syntaxin-binding protein 1 (STXBP1) mutations.